A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Study ID: 3782
NCT Number: NCT06338995
Principal Investigator: Christine Franzese, MD
Department: Otolaryngology
Eligibility: Both men and women 18 years old to 100 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026